<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03520517</url>
  </required_header>
  <id_info>
    <org_study_id>BHV0223-103</org_study_id>
    <nct_id>NCT03520517</nct_id>
  </id_info>
  <brief_title>Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS</brief_title>
  <official_title>Open-Label Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of BHV-0223 in Subjects With Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biohaven Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cognitive Research Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Biohaven Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1, open-label study of BHV-0223 in ALS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 1, open-label, single arm study to evaluate the safety, tolerability and&#xD;
      pharmacokinetics of multiple doses of BHV-0223 in subjects with ALS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2, 2018</start_date>
  <completion_date type="Actual">October 8, 2018</completion_date>
  <primary_completion_date type="Actual">October 8, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events (Safety and Tolerability)</measure>
    <time_frame>Through Week 8 (Day 57)</time_frame>
    <description>Incidence of treatment emergent adverse events (safety and tolerability) as measured through laboratory tests and physical exam findings.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BHV-0223 Concentrations in Blood at Days 1, 29 and 57</measure>
    <time_frame>Through Week 8 (Day 57)</time_frame>
    <description>BHV-0223 concentrations at days 1, 29 and 57 through blood collections at days 1, 29 and 57.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>ALS</condition>
  <condition>Lou Gehrig Disease</condition>
  <condition>Lou Gehrig's Disease</condition>
  <condition>Lou-Gehrigs Disease</condition>
  <condition>Motor Neuron Disease, Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>BHV-0223</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>riluzole 40 mg sublingual tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BHV-0223</intervention_name>
    <description>BHV-0223, 40 mg BID</description>
    <arm_group_label>BHV-0223</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects with diagnosed ALS by the revised El Escorial diagnostic criteria, including&#xD;
             laboratory supported probable, probable, or definite ALS;&#xD;
&#xD;
          2. Subjects who have never taken riluzole tablets, OR Subjects who previously took&#xD;
             riluzole tablets but discontinued at least 1 month prior to the screening visit.&#xD;
             Subjects must not have had ALT or AST &gt; 5 x ULN while taking riluzole tablets, or any&#xD;
             other clinically significant tolerability issues (e.g., hypersensitivity reactions) in&#xD;
             the judgement of the investigator;&#xD;
&#xD;
          3. Subjects determined by the investigator to be medically stable;&#xD;
&#xD;
          4. Subjects determined by the investigator to be willing and physically able to complete&#xD;
             the study as designed, with or without caregiver assistance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Target Disease Exceptions&#xD;
&#xD;
          2. Medical History Exceptions&#xD;
&#xD;
               1. Subject is known to have a current diagnosis of acute or chronic viral hepatitis;&#xD;
&#xD;
               2. Subject is known to have any other acute or chronic liver disease that is&#xD;
                  clinically significant in the investigator's judgment;&#xD;
&#xD;
               3. Subject has a history of a clinically significant medical condition that would&#xD;
                  interfere with the subject's ability to comply with study instructions, would&#xD;
                  place the subject at increased risk, or might confound the interpretation of the&#xD;
                  study results in the investigator's judgment;&#xD;
&#xD;
               4. Any other sound medical, psychiatric and/or social reason in the investigator's&#xD;
                  judgment;&#xD;
&#xD;
          3. Physical and Laboratory Test Findings&#xD;
&#xD;
               1. Positive urine pregnancy test in WOCBP at screening;&#xD;
&#xD;
               2. Subject has evidence of organ dysfunction or any clinically significant deviation&#xD;
                  from normal in physical examination, vital signs, or other determinations beyond&#xD;
                  what is consistent with the target population, in the investigator's judgment;&#xD;
&#xD;
               3. Subject has liver function testing abnormalities (ALT, AST , or total bilirubin)&#xD;
                  that are &gt; 1 x ULN;&#xD;
&#xD;
          4. Other Exclusions a. Subjects who are unable to be compliant with the visit schedule or&#xD;
             protocol procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Holy Cross Neuroscience Research Institute</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somnos/Neurology Associates Clinical Research</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurosciences Institute, Neurology - Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wesley Neurology Clinic</name>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Neurology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 17, 2018</study_first_submitted>
  <study_first_submitted_qc>May 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2018</study_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>ALS</keyword>
  <keyword>Biohaven</keyword>
  <keyword>Motor Neuron Disease, Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Lou Gehrig's Disease</keyword>
  <keyword>Lou-Gehrigs Disease</keyword>
  <keyword>Lou Gehrig Disease</keyword>
  <keyword>Riluzole</keyword>
  <keyword>RilutekÂ®</keyword>
  <keyword>Neuroprotective Agents</keyword>
  <keyword>Administration, Sublingual</keyword>
  <keyword>Administration, Oral</keyword>
  <keyword>Biological Availability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

